{"product_id":"straumann-bcg-matrix","title":"Straumann Holding Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eStraumann Holding’s BCG Matrix preview highlights its implant and digital dentistry segments as potential Stars with strong growth and market share, while legacy prosthetics may appear as Cash Cows generating steady cash—yet deeper shifts in market dynamics suggest some product lines could be Question Marks ripe for investment or reallocation. Purchase the full BCG Matrix for a complete quadrant-by-quadrant breakdown, data-driven recommendations, and actionable strategies to optimize portfolio performance and capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium Dental Implant Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStraumann’s premium implant lines, led by BLX and TLX, held roughly 28%–30% of the global premium implant market in 2024, with BLX\/TLX revenues up ~16% YoY to an estimated CHF 620m driven by immediate-loading protocols that cut treatment time by 30% on average.\u003c\/p\u003e\n\u003cp\u003eThese portfolios keep leading share but need ongoing R\u0026amp;D and global marketing spend—Straumann invested CHF 130m in R\u0026amp;D in 2024—to defend versus digital\/high-tech rivals.\u003c\/p\u003e\n\u003cp\u003eThe shift to fully tapered implants is a high-growth niche (estimated CAGR 12%–15% to 2028); Straumann remains the primary innovator, launching 3 major tapered SKUs in 2024 to cement leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Dentistry Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntegration of Straumann’s intraoral scanners and Virtuo Vivo platform drives high growth as clinics shift to digital: global dental CAD\/CAM market hit $3.9B in 2024 and is forecasted to grow at 11.2% CAGR to 2030, boosting scanner adoption and software subscriptions.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D spend is heavy—Straumann invested ~CHF 115M in 2024—yet this maintains tech edge and captures rising cohort of tech-savvy clinicians, where 38% of EU\/US clinics reported full digital workflows in 2024.\u003c\/p\u003e\n\u003cp\u003eThis segment locks customers into Straumann’s prosthetic ecosystem, raising lifetime revenue per practice via consumables and prosthetics; digital-integrated accounts show ~25% higher annual spend versus non-digital peers in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDespite China’s volume-based procurement, Straumann held ~25% implant market share in 2024 and posted mid-20% volume CAGR 2019–24, showing rapid growth in procedures.\u003c\/p\u003e\n\u003cp\u003eThe multi-brand approach—premium Straumann, mid-tier Neodent, and value lines—captures price points from ¥3,000 to ¥18,000 per implant, requiring ~¥1.2–1.5bn cumulative local capex through 2025 for plants, clinics, and training.\u003c\/p\u003e\n\u003cp\u003eChina is a Star: urbanization pushed dental service penetration from ~20% to ~32% (2015–24), and ~300m untapped patients justify continued high capital allocation and double-digit ROI expectations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegenerative Solutions and Biomaterials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe biomaterials unit, led by Emdogain and bone graft substitutes, is in high growth—global surgical dental biomaterials grew ~7.8% CAGR 2020–2025, with Straumann capturing ~25% dental biomaterials share in 2024 and biomaterials contributing ~18% of group sales (€264m of €1.47bn in 2024).\u003c\/p\u003e\n\u003cp\u003eStrong market position but needs ongoing promotion to train GPs in surgical techniques; aging populations and rising implant demand keep this unit a strategic growth pillar.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: ~7.8% CAGR 2020–2025\u003c\/li\u003e\n\u003cli\u003eStraumann share: ~25% (2024)\u003c\/li\u003e\n\u003cli\u003eGroup sales: biomaterials €264m of €1.47bn (2024)\u003c\/li\u003e\n\u003cli\u003eKey need: continuous GP surgical education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and Educational Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe ITI partnership and Straumann’s proprietary platforms are stars: they drive high growth by building brand loyalty and setting certification standards, helping Straumann capture new clinicians; Straumann Academy reported over 120,000 course completions in 2024 and ITI membership exceeded 16,000 clinicians globally as of Dec 2024.\u003c\/p\u003e\n\u003cp\u003eThese services need continuous content updates and platform maintenance—Straumann spent ~€45m on digital education and R\u0026amp;D in FY 2024—to match fast-evolving implant and digital-dentistry tech.\u003c\/p\u003e\n\u003cp\u003eBy leading clinician education, Straumann keeps its high-share implant systems top-of-mind for trainees, supporting repeat purchases and premium pricing; surveys show 68% of newly certified implantologists prefer Straumann products within 24 months of training (2023–24 data).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120,000+ course completions (Straumann Academy, 2024)\u003c\/li\u003e\n\u003cli\u003e16,000+ ITI members (Dec 2024)\u003c\/li\u003e\n\u003cli\u003e€45m digital education\/R\u0026amp;D spend (FY 2024)\u003c\/li\u003e\n\u003cli\u003e68% preference rate among new implantologists (2023–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStraumann’s growth engines: premium implants, biomaterials, China \u0026amp; education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStraumann’s Stars: premium implants, biomaterials, China \u0026amp; education drive high growth and recurring revenue—BLX\/TLX ~CHF 620m (2024), premium implant share 28%–30%, biomaterials €264m (18% group sales), Straumann Academy 120,000+ completions (2024), China implant share ~25% with rapid penetration rise.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBLX\/TLX revenue\u003c\/td\u003e\n\u003ctd\u003e~CHF 620m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePremium share\u003c\/td\u003e\n\u003ctd\u003e28%–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomaterials\u003c\/td\u003e\n\u003ctd\u003e€264m (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademy completions\u003c\/td\u003e\n\u003ctd\u003e120,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina implant share\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG review of Straumann’s units with strategic actions for Stars, Cash Cows, Question Marks, and Dogs, plus trend-driven investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Straumann business unit in a quadrant for fast portfolio prioritization and executive decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Tissue Level Implants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe classic Tissue Level implant by Straumann remains the industry gold standard, delivering steady high-margin revenue—Straumann reported implant sales growth of 6.8% in 2024, with implants contributing roughly 42% of group gross profit—requiring minimal marketing due to strong brand trust.\u003c\/p\u003e\n\u003cp\u003eAs a mature product with a massive installed base, Tissue Level implants generate significant cash flow; Straumann’s operating cash flow was CHF 565m in FY 2024, funds used to invest in digital workflows and R\u0026amp;D for newer implant lines.\u003c\/p\u003e\n\u003cp\u003eIts reliability keeps long-term practitioners loyal—implant system churn rates under 5% in clinical surveys—so Tissue Level acts as a classic cash cow funding innovation while sustaining margin stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConventional Prosthetic Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard abutments and restorative components for traditional implant cases sit in a mature global market where Straumann Holding AG (SRA) holds a leading share—about 30–35% of the premium implant prosthetics segment in 2024—driving stable volumes. These components scale efficiently, with incremental production costs under 10% of selling price, supporting gross margins above 60% in 2024. Cash flow from these cash cows funded ~€250m of net interest and helped maintain a dividend payout of €2.00 per share in 2024. This steady cash generation reduces leverage and underpins capital allocation to R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBone Level (BLT) Legacy Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe original Bone Level Tapered (BLT) implants now sit in Straumann Holding’s mature segment, holding roughly 35%–40% market share in established clinics in Europe and North America as of 2025 and producing steady unit sales growth near 2% YoY.\u003c\/p\u003e\n\u003cp\u003eGrowth has stabilized versus BLX lines, so BLT requires minimal promo spend—marketing and training costs under 5% of line revenues—boosting margin contribution.\u003c\/p\u003e\n\u003cp\u003eBLT continues to harvest repeat purchases from a loyal clinician base prioritizing proven outcomes; customer retention exceeds 80% and line EBITDA margin is near 28% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMaintenance and Surgical Instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe sale of Straumann’s specialized surgical kits, drills, and maintenance tools is a high-market-share cash cow in a slow-growth dental consumables category; Straumann reported group net sales of CHF 2.1bn in dental implants \u0026amp; instruments in 2024, with instruments comprising a stable low-single-digit growth slice.\u003c\/p\u003e\n\u003cp\u003eClinic lock-in to Straumann’s proprietary instruments creates recurring, predictable service revenue and gross margins near 60%, while R\u0026amp;D for these metal tools is minimal versus digital platforms.\u003c\/p\u003e\n\u003cp\u003eThat low-R\u0026amp;D, high-margin flow lets Straumann redirect cash to higher-risk digital initiatives like coDiagnostiX and implantology software, which accounted for ~5% of revenues in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh share in mature market; stable unit demand\u003c\/li\u003e\n\u003cli\u003eClinic lock-in = recurring, predictable cash\u003c\/li\u003e\n\u003cli\u003eMinimal R\u0026amp;D; ~60% gross margins\u003c\/li\u003e\n\u003cli\u003eFunds digital bets (~5% revenue in 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Laboratory Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCore laboratory services—traditional dental lab work and milling centers for standard crowns and bridges—generated about CHF 360m in 2024 revenues for Straumann Holding, offering steady cashflow from a mature market while keeping unit costs low via scalable logistics and ISO-certified quality controls.\u003c\/p\u003e\n\u003cp\u003eThese low-capex operations convert margin into free cash flow, funding high-growth areas: clear aligners (expected 20–25% CAGR through 2026) and digital dentistry investments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ~CHF 360m\u003c\/li\u003e\n\u003cli\u003eLow capital intensity, high FCF conversion\u003c\/li\u003e\n\u003cli\u003eMature market, stable margins\u003c\/li\u003e\n\u003cli\u003eFunds clear aligner + digital growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStraumann’s cash cows fund fast-growing digital \u0026amp; clear-aligner surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStraumann cash cows (Tissue Level, BLT, instruments, labs) delivered steady high-margin cash: group OCF CHF 565m FY2024; implants ≈42% gross profit; instruments \u0026amp; components gross margins ~60%; BLT EBITDA ~28%; lab revenue CHF 360m 2024. These fund digital\/clear-aligner growth (~5% revenue from software; clear aligners 20–25% CAGR to 2026).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eMargin\/Notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTissue Level\u003c\/td\u003e\n\u003ctd\u003eImplant sales +6.8%\u003c\/td\u003e\n\u003ctd\u003e~42% group GP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBLT\u003c\/td\u003e\n\u003ctd\u003eSales growth ~2% YoY\u003c\/td\u003e\n\u003ctd\u003eEBITDA ~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstruments\u003c\/td\u003e\n\u003ctd\u003ePart of CHF 2.1bn implants\u0026amp;instruments\u003c\/td\u003e\n\u003ctd\u003eGross margin ~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs\u003c\/td\u003e\n\u003ctd\u003eRevenue CHF 360m\u003c\/td\u003e\n\u003ctd\u003eHigh FCF conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eStraumann Holding BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Straumann Holding BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, market-informed strategic report ready for immediate use. This preview mirrors the final downloadable document, crafted by industry analysts for clarity and decision-making, and will be delivered directly to your inbox with no surprises or additional revisions required. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748121424249,"sku":"straumann-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/straumann-bcg-matrix.png?v=1772205023","url":"https:\/\/matrixbcg.com\/products\/straumann-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}